Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia

Stopped This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.

Conditions

• Fibromyalgia

Interventions

• DRUG: [S,S]-Reboxetine

Sponsor

Pfizer